Loading…
Astal Laboratories (BSE 512600)₹59.93−0.12%Pharmaceuticals
In the Jun 2026 quarter (consolidated), Astal Laboratories reported sales of ₹101 Cr and net profit of ₹9.45 Cr. For the year to Mar 2026, sales were ₹249 Cr and net profit ₹15.05 Cr.
Company filings, consolidated accounts; latest reported quarter Jun 2026
| Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 23.50 | 52.32 | 134 | 101 |
| Expenses | 19.25 | 48.59 | 124 | 88.45 |
| Operating Profit | 4.20 | 3.57 | 10.23 | 12.29 |
| OPM % | 17.9% | 6.9% | 7.7% | 12.2% |
| Other Income | 0.05 | 0.05 | 0.11 | 0.15 |
| Interest | 0.28 | 0.32 | 1.10 | 1.19 |
| Depreciation | 0.09 | 0.13 | 0.85 | 0.85 |
| Profit before tax | 3.84 | 3.13 | 8.31 | 10.32 |
| Tax % | 28.6% | 24.6% | 8.0% | 9.1% |
| Net Profit | 2.75 | 2.37 | 7.70 | 9.45 |
| EPS (Rs) | 2.78 | 2.18 | 1.81 | 2.14 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Sales | 64.09 | 249 |
| Expenses | 50.89 | 228 |
| Operating Profit | 13.05 | 21.09 |
| OPM % | 20.1% | 8.1% |
| Other Income | 0.00 | 0.00 |
| Interest | 1.01 | 2.01 |
| Depreciation | 0.00 | 0.99 |
| Profit before tax | 11.95 | 17.93 |
| Tax % | 25.0% | 17.1% |
| Net Profit | 9.04 | 15.05 |
| EPS (Rs) | 9.07 | 3.47 |
| Dividend payout % | 0.0% | 0.0% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 10.02 | 42.11 |
| Reserves | 26.01 | 292 |
| Borrowings | 12.97 | 49.91 |
| Other Liabilities | 14.01 | 135 |
| Total Liabilities | 63.01 | 518 |
| Fixed Assets | 11.04 | 269 |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 |
| Other Assets | 51.97 | 251 |
| Inventories | 15.03 | 68.06 |
| Trade receivables | 28.01 | 156 |
| Cash & equivalents | 2.01 | 1.01 |
| Total Assets | 63.01 | 518 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | −12.96 | −17.93 |
| Cash from investing activity | −7.98 | −1.99 |
| Cash from financing activity | 2.99 | 3.01 |
| Net cash flow | −16.99 | −17.01 |
| Capex | 5.79 | 1.38 |
| Free cash flow | −18.02 | −19.04 |
| CFO / OP % | −96.1% | −80.1% |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor days | 157 | 229 |
| Inventory days | 112 | 113 |
| Days payable | 82 | 206 |
| Cash conversion cycle | 188 | 136 |
| Working capital days | 97 | 114 |
| ROCE % | — | 9.0% |
For the Jun 2026 quarter, Astal Laboratories reported sales of ₹101 Cr and net profit of ₹9.45 Cr. The operating margin was 12.2%.
Astal Laboratories' sales for the year to Mar 2026 were ₹249 Cr.
Net profit for the year to Mar 2026 was ₹15.05 Cr. Earnings per share over the same trailing period were ₹3.47.
Astal Laboratories reported borrowings of ₹49.91 Cr at Mar 2026, against cash and equivalents of ₹1.01 Cr.
Cash from operations was −₹17.93 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹19.04 Cr.